Fortress Biotech Inc. (FBIO) Financial Statements (2024 and earlier)
Company Profile
Business Address |
1111 KANE CONCOURSE BAY HARBOR ISLANDS, FL 33154 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 80,927 | 178,266 | 305,744 | 233,351 | 136,858 | 83,112 | |||
Cash and cash equivalents | 80,927 | 178,266 | 305,744 | 233,351 | 136,858 | 65,508 | |||
Short-term investments | 17,604 | ||||||||
Receivables | 15,222 | 28,346 | 23,790 | 20,093 | 14,404 | 5,510 | |||
Inventory, net of allowances, customer advances and progress billings | 10,206 | 14,159 | 9,862 | 1,404 | 857 | 678 | |||
Inventory | 10,206 | 14,159 | 9,862 | 1,404 | 857 | 678 | |||
Disposal group, including discontinued operation | 13,089 | ||||||||
Other undisclosed current assets | 10,667 | 9,661 | 7,066 | 6,723 | 4,133 | 8,818 | |||
Total current assets: | 117,022 | 230,432 | 346,462 | 261,571 | 156,252 | 111,207 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 16,990 | 19,991 | 19,005 | 20,487 | 21,480 | ✕ | |||
Property, plant and equipment | 6,505 | 13,020 | 15,066 | 11,923 | 12,433 | 12,019 | |||
Long-term investments and receivables | 17,566 | 11,148 | |||||||
Long-term investments | 17,566 | 11,148 | |||||||
Intangible assets, net (including goodwill) | 20,287 | 27,197 | 12,552 | 14,629 | 7,377 | 1,417 | |||
Intangible assets, net (excluding goodwill) | 20,287 | 27,197 | 12,552 | 14,629 | 7,377 | 1,417 | |||
Restricted cash and investments | 2,438 | 2,688 | 2,220 | 1,645 | 16,574 | 16,074 | |||
Other noncurrent assets | 4,284 | 973 | 1,198 | 1,013 | 1,158 | 276 | |||
Total noncurrent assets: | 50,504 | 63,869 | 50,041 | 67,263 | 70,170 | 29,786 | |||
TOTAL ASSETS: | 167,526 | 294,301 | 396,503 | 328,834 | 226,422 | 140,993 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 73,562 | 97,446 | 90,660 | 40,674 | 35,451 | 34,067 | |||
Interest and dividends payable | ✕ | ✕ | ✕ | 1,042 | 1,232 | ||||
Taxes payable | ✕ | ✕ | ✕ | 345 | 136 | ||||
Accounts payable | |||||||||
Accrued liabilities | 73,562 | 97,446 | 90,660 | 29,262 | 25,399 | 16,360 | |||
Other undisclosed accounts payable and accrued liabilities | (345) | 11,276 | 9,010 | 16,475 | |||||
Deferred revenue | 728 | 2,611 | ✕ | ||||||
Debt | 2,948 | 812 | 1,784 | 9,914 | |||||
Derivative instruments and hedges, liabilities | 27 | 991 | |||||||
Other liabilities | 163 | 268 | 5,300 | ||||||
Due to related parties | ✕ | ✕ | 7,220 | 149 | |||||
Other undisclosed current liabilities | 11,183 | 26,325 | 6,959 | 1,985 | 1,134 | 10,493 | |||
Total current liabilities: | 84,908 | 127,715 | 101,042 | 47,959 | 45,616 | 55,614 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 60,856 | 91,730 | 63,924 | 74,568 | 101,148 | 60,425 | |||
Long-term debt, excluding current maturities | 60,856 | 91,730 | 42,937 | 51,677 | 77,436 | 60,425 | |||
Liabilities, other than long-term debt | 20,175 | 23,419 | 2,033 | 1,949 | 7,126 | 5,211 | |||
Other liabilities | 1,893 | 1,847 | 2,033 | 1,949 | 7,126 | 5,211 | |||
Operating lease, liability | 18,282 | 21,572 | 20,987 | 22,891 | 23,712 | ✕ | |||
Other undisclosed noncurrent liabilities | 1,412 | 3,627 | 7,359 | ||||||
Total noncurrent liabilities: | 81,031 | 116,561 | 69,584 | 83,876 | 108,274 | 65,636 | |||
Total liabilities: | 165,939 | 244,276 | 170,626 | 131,835 | 153,890 | 121,250 | |||
Equity | |||||||||
Equity, attributable to parent | 22,544 | 41,721 | 108,674 | 100,338 | 26,215 | 1,852 | |||
Preferred stock | 3 | 3 | 3 | 3 | 1 | 1 | |||
Common stock | 15 | 110 | 101 | 95 | 74 | 58 | |||
Common stock, value, subscriptions | 500 | 659 | |||||||
Additional paid in capital | 717,396 | 675,841 | 656,033 | 583,000 | 461,874 | 397,408 | |||
Accumulated deficit | (694,870) | (634,233) | (547,463) | (482,760) | (436,234) | (396,274) | |||
Equity, attributable to noncontrolling interest | (20,957) | 8,304 | 117,203 | 96,661 | 46,317 | 17,891 | |||
Total equity: | 1,587 | 50,025 | 225,877 | 196,999 | 72,532 | 19,743 | |||
TOTAL LIABILITIES AND EQUITY: | 167,526 | 294,301 | 396,503 | 328,834 | 226,422 | 140,993 |
Income Statement (P&L) ($ in thousands)
6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 84,513 | 75,743 | 68,791 | 45,599 | 36,629 | 26,882 | ||
Other income | 19,519 | 2,674 | ||||||
Cost of revenue | (132,731) | (165,651) | (41,576) | (78,703) | (18,376) | (6,125) | ||
Cost of goods and services sold | (26,660) | (30,775) | (32,084) | (14,594) | (10,532) | (6,125) | ||
Gross profit: | (48,218) | (89,908) | 27,215 | (33,104) | 18,253 | 20,757 | ||
Operating expenses | (94,124) | (113,656) | (215,756) | (61,166) | (129,072) | (146,879) | ||
Other undisclosed operating income | 6,125 | |||||||
Operating loss: | (142,342) | (203,564) | (188,541) | (94,270) | (110,819) | (119,997) | ||
Nonoperating income (expense) | (11,291) | (9,900) | 24,188 | (8,579) | 9,159 | (10,803) | ||
Investment income, nonoperating | 3,003 | 1,398 | 649 | 1,518 | 2,559 | 1,172 | ||
Other nonoperating expense | (3,403) | |||||||
Interest and debt expense | (2,796) | (12,482) | (15,308) | (617) | (3) | (2) | ||
Other undisclosed income from continuing operations before equity method investments, income taxes | 617 | 3 | 2 | |||||
Loss from continuing operations before equity method investments, income taxes: | (156,429) | (225,946) | (179,661) | (102,849) | (101,660) | (130,800) | ||
Other undisclosed income from continuing operations before income taxes | 2,796 | 12,482 | 15,308 | |||||
Loss from continuing operations before income taxes: | (153,633) | (213,464) | (164,353) | (102,849) | (101,660) | (130,800) | ||
Income tax expense | (521) | (449) | (473) | (136) | ||||
Loss from continuing operations: | (154,154) | (213,913) | (164,826) | (102,985) | (101,660) | (130,800) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (164,826) | (102,985) | (101,660) | (141,936) | |
Loss from discontinued operations | (11,136) | |||||||
Other undisclosed net income | ||||||||
Net loss: | (154,154) | (213,913) | (164,826) | (102,985) | (101,660) | (141,936) | ||
Net income attributable to noncontrolling interest | 93,517 | 127,338 | 100,123 | 56,459 | 61,700 | 57,789 | ||
Net loss attributable to parent: | (60,637) | (86,575) | (64,703) | (46,526) | (39,960) | (84,147) | ||
Preferred stock dividends and other adjustments | (8,032) | |||||||
Other undisclosed net loss available to common stockholders, basic | ||||||||
Net loss available to common stockholders, diluted: | (68,669) | (86,575) | (64,703) | (46,526) | (39,960) | (84,147) |
Comprehensive Income ($ in thousands)
6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (154,154) | (213,913) | (164,826) | (102,985) | (101,660) | (141,936) | ||
Comprehensive loss: | (154,154) | (213,913) | (164,826) | (102,985) | (101,660) | (141,936) | ||
Comprehensive income, net of tax, attributable to noncontrolling interest | 93,517 | 127,338 | 100,123 | 56,459 | 61,700 | 57,789 | ||
Comprehensive loss, net of tax, attributable to parent: | (60,637) | (86,575) | (64,703) | (46,526) | (39,960) | (84,147) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.